Robert W Ross
Overview
Explore the profile of Robert W Ross including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
1670
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ruiz-Gaviria R, Marroquin-Rivera A, Pardi M, Ross R
J Infect Chemother
. 2023 Mar;
29(7):646-653.
PMID: 36898501
Background: Community acquired pneumonia (CAP) is the most frequent cause of mortality secondary to infectious etiologies. Recommendations about the use of blood cultures in the diagnosis and treatment of CAP...
2.
Surani A, Slama E, Thomas S, Ross R, Cunningham S
IDCases
. 2020 Mar;
20:e00736.
PMID: 32211296
is a Gram-negative rod belonging to the family and closely related to spp. It is commonly present in aquatic environments. Human infections caused by are being increasingly recognized. It has...
3.
Thompson A, Walters M, Kwiatkowski J, Rasko J, Ribeil J, Hongeng S, et al.
N Engl J Med
. 2018 Apr;
378(16):1479-1493.
PMID: 29669226
Background: Donor availability and transplantation-related risks limit the broad use of allogeneic hematopoietic-cell transplantation in patients with transfusion-dependent β-thalassemia. After previously establishing that lentiviral transfer of a marked β-globin (β)...
4.
Ribeil J, Hacein-Bey-Abina S, Payen E, Magnani A, Semeraro M, Magrin E, et al.
N Engl J Med
. 2017 Mar;
376(9):848-855.
PMID: 28249145
Sickle cell disease results from a homozygous missense mutation in the β-globin gene that causes polymerization of hemoglobin S. Gene therapy for patients with this disorder is complicated by the...
5.
McKay R, Zurita A, Werner L, Bruce J, Carducci M, Stein M, et al.
J Clin Oncol
. 2016 Apr;
34(16):1913-20.
PMID: 27044933
Purpose: Patients with recurrent prostate cancer after local treatment make up a heterogeneous population for whom androgen deprivation therapy (ADT) is the usual treatment. The purpose of this randomized phase...
6.
Choueiri T, Jacobus S, Bellmunt J, Qu A, Appleman L, Tretter C, et al.
J Clin Oncol
. 2014 May;
32(18):1889-94.
PMID: 24821883
Purpose: In advanced urothelial cancer, treatment with dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) results in a high response rate, less toxicity, and few dosing delays. We explored the efficacy...
7.
Jimeno A, Weiss G, Miller Jr W, Gettinger S, Eigl B, Chang A, et al.
Clin Cancer Res
. 2013 Apr;
19(10):2766-74.
PMID: 23575478
Purpose: To conduct a first-in-human phase I study to determine the dose-limiting toxicities (DLT), characterize the pharmacokinetic profile, and document the antitumor activity of IPI-926, a new chemical entity that...
8.
Ross R, Galsky M, Scher H, Magidson J, Wassmann K, Lee G, et al.
Lancet Oncol
. 2012 Oct;
13(11):1105-13.
PMID: 23059047
Background: Survival for patients with castration-resistant prostate cancer is highly variable. We assessed the effectiveness of a whole-blood RNA transcript-based model as a prognostic biomarker in castration-resistant prostate cancer. Methods:...
9.
Thomas S, Waterman P, Chen S, Marinelli B, Seaman M, Rodig S, et al.
J Nanomed Nanotechnol
. 2012 Feb;
2(112).
PMID: 22319675
Prostate cancer is the most commonly diagnosed non-skin malignancy in the United States and presents with a wide range of aggressiveness from extremely slow-growing to highly aggressive. There is a...
10.
Ross R, Galsky M, Febbo P, Barry M, Richie J, Xie W, et al.
Cancer
. 2012 Jan;
118(19):4777-84.
PMID: 22282219
Background: Treatment of high-risk localized prostate cancer remains inadequate. The authors performed a phase 2 multicenter trial of neoadjuvant docetaxel plus bevacizumab before radical prostatectomy. Methods: Eligibility included any of...